Ariad Patent Claims In Suit V. Eli Lilly Invalid: Court

Law360, New York (April 9, 2009, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit has handed a win to drugmaker Eli Lilly & Co. in a long-running patent battle launched by Ariad Pharmaceuticals Inc. over the drugs Evista and Xigris, finding four claims of Ariad's patent invalid.

In a decision issued April 3, the Federal Circuit tossed the patent claims asserted against Lilly related to Evista, an osteoporosis treatment, and Xigris, a treatment for severe sepsis, ruling that those four claims of the Ariad patent were invalid because the written descriptions...
To view the full article, register now.